Improved positron emission tomography imaging of glioblastoma cancer using novel 68Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR)

@article{Loft2017ImprovedPE,
  title={Improved positron emission tomography imaging of glioblastoma cancer using novel 68Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR)},
  author={Mathias Loft and Yao Sun and C. Liu and C. Christensen and Daijuan Huang and A. Kjaer and Z. Cheng},
  journal={Amino Acids},
  year={2017},
  volume={49},
  pages={1089-1100}
}
  • Mathias Loft, Yao Sun, +4 authors Z. Cheng
  • Published 2017
  • Chemistry, Medicine
  • Amino Acids
  • The urokinase-type plasminogen activator receptor (uPAR) is overexpressed in several cancers including glioblastoma (GBM) and is an established biomarker for metastatic potential. The uPAR-targeting peptide AE105-NH2 (Ac-Asp-Cha-Phe-(D)Ser-(D)Arg-Tyr-Leu-Trp-Ser-CONH2) is a promising candidate for non-invasive positron emission tomography (PET) imaging of uPAR. Despite the optimal physical properties of 68Ga for peptide-based PET imaging, low tumor uptakes have previously been reported using… CONTINUE READING
    3 Citations

    References

    SHOWING 1-10 OF 27 REFERENCES
    First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.
    • 31
    Imaging of Urokinase-Type Plasminogen Activator Receptor Expression Using a 64Cu-Labeled Linear Peptide Antagonist by microPET
    • 65
    • PDF
    Quantitative PET of Human Urokinase-Type Plasminogen Activator Receptor with 64Cu-DOTA-AE105: Implications for Visualizing Cancer Invasion
    • 53
    • PDF
    Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma
    • 15
    • Highly Influential
    • PDF
    First-in-human uPAR PET: Imaging of Cancer Aggressiveness
    • 56
    • PDF